110 related articles for article (PubMed ID: 12960909)
1. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury.
Chiou-Tan FY; Garza H; Chan KT; Parsons KC; Donovan WH; Robertson CS; Holmes SA; Graves DE; Rintala DH
Am J Phys Med Rehabil; 2003 Sep; 82(9):678-85. PubMed ID: 12960909
[TBL] [Abstract][Full Text] [Related]
2. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
[TBL] [Abstract][Full Text] [Related]
3. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Arnold JD; Dart BW; Barker DE; Maxwell RA; Burkholder HC; Mejia VA; Smith PW; Longley JM
Am Surg; 2010 Jun; 76(6):563-70. PubMed ID: 20583509
[TBL] [Abstract][Full Text] [Related]
4. Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis.
Krotenberg R; Adler U; Pomeranz B; Miller JD; Russell MW
Am J Phys Med Rehabil; 2001 Dec; 80(12):889-95. PubMed ID: 11821667
[TBL] [Abstract][Full Text] [Related]
5. Selecting an agent for prophylaxis of venous thromboembolism.
Myers J
Am J Health Syst Pharm; 2006 Dec; 63(24):2448-50. PubMed ID: 17158692
[No Abstract] [Full Text] [Related]
6. Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury.
Hebbeler SL; Marciniak CM; Crandall S; Chen D; Nussbaum S; Mendelewski S
J Spinal Cord Med; 2004; 27(3):236-40. PubMed ID: 15478526
[TBL] [Abstract][Full Text] [Related]
7. Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data.
Wade WE; Spruill WJ
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):619-25. PubMed ID: 11734661
[TBL] [Abstract][Full Text] [Related]
8. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
9. Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning.
Schwarcz TH; Quick RC; Minion DJ; Kearney PA; Kwolek CJ; Endean ED
J Vasc Surg; 2001 Sep; 34(3):447-52. PubMed ID: 11533596
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of thromboembolism in spinal injuries--results of enoxaparin used in 276 patients.
Deep K; Jigajinni MV; McLean AN; Fraser MH
Spinal Cord; 2001 Feb; 39(2):88-91. PubMed ID: 11402364
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.
Carson W; Schilling B; Simons WR; Parks C; Choe Y; Faria C; Powers A
J Pharm Pract; 2012 Apr; 25(2):180-9. PubMed ID: 21987527
[TBL] [Abstract][Full Text] [Related]
12. [Prophylaxis of venous thromboembolism in acutely ill medical patients].
RodrÃguez A; Vallano A
Med Clin (Barc); 2006 May; 126(19):754-6. PubMed ID: 16759593
[No Abstract] [Full Text] [Related]
13. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Wade WE; Spruill WJ; Leslie RB
Am J Orthop (Belle Mead NJ); 2003 Apr; 32(4):201-5. PubMed ID: 12723772
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
15. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Bauer KA; Eriksson BI; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1305-10. PubMed ID: 11794149
[TBL] [Abstract][Full Text] [Related]
16. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
17. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
[TBL] [Abstract][Full Text] [Related]
18. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
[TBL] [Abstract][Full Text] [Related]
19. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
[TBL] [Abstract][Full Text] [Related]
20. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
